JP2020127437A5 - - Google Patents

Download PDF

Info

Publication number
JP2020127437A5
JP2020127437A5 JP2020096798A JP2020096798A JP2020127437A5 JP 2020127437 A5 JP2020127437 A5 JP 2020127437A5 JP 2020096798 A JP2020096798 A JP 2020096798A JP 2020096798 A JP2020096798 A JP 2020096798A JP 2020127437 A5 JP2020127437 A5 JP 2020127437A5
Authority
JP
Japan
Prior art keywords
seq
subject
absence
disease
genotyping assay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020096798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020127437A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020127437A publication Critical patent/JP2020127437A/ja
Publication of JP2020127437A5 publication Critical patent/JP2020127437A5/ja
Priority to JP2022093628A priority Critical patent/JP2022111329A/ja
Priority to JP2024213907A priority patent/JP2025023316A/ja
Withdrawn legal-status Critical Current

Links

JP2020096798A 2013-05-17 2020-06-03 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 Withdrawn JP2020127437A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022093628A JP2022111329A (ja) 2013-05-17 2022-06-09 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
JP2024213907A JP2025023316A (ja) 2013-05-17 2024-12-06 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361824932P 2013-05-17 2013-05-17
US61/824,932 2013-05-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018124311A Division JP2018148931A (ja) 2013-05-17 2018-06-29 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022093628A Division JP2022111329A (ja) 2013-05-17 2022-06-09 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体

Publications (2)

Publication Number Publication Date
JP2020127437A JP2020127437A (ja) 2020-08-27
JP2020127437A5 true JP2020127437A5 (enExample) 2020-10-08

Family

ID=51899024

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016514143A Active JP6482533B2 (ja) 2013-05-17 2014-05-16 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
JP2018124311A Withdrawn JP2018148931A (ja) 2013-05-17 2018-06-29 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
JP2020096798A Withdrawn JP2020127437A (ja) 2013-05-17 2020-06-03 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
JP2022093628A Withdrawn JP2022111329A (ja) 2013-05-17 2022-06-09 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
JP2024213907A Pending JP2025023316A (ja) 2013-05-17 2024-12-06 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2016514143A Active JP6482533B2 (ja) 2013-05-17 2014-05-16 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
JP2018124311A Withdrawn JP2018148931A (ja) 2013-05-17 2018-06-29 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022093628A Withdrawn JP2022111329A (ja) 2013-05-17 2022-06-09 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
JP2024213907A Pending JP2025023316A (ja) 2013-05-17 2024-12-06 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体

Country Status (7)

Country Link
US (4) US20160090629A1 (enExample)
EP (3) EP3498867B1 (enExample)
JP (5) JP6482533B2 (enExample)
KR (4) KR102295125B1 (enExample)
CN (1) CN105358713B (enExample)
ES (1) ES2894963T3 (enExample)
WO (1) WO2014186750A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
BR112014007426B1 (pt) 2011-09-30 2023-01-03 Teva Pharmaceuticals Australia Pty Ltd Anticorpos contra tl1a e seus usos
EP3639841B1 (en) 2013-03-27 2023-09-06 Cedars-Sinai Medical Center Treating fibrosis by inhibiting tl1a
KR102295125B1 (ko) 2013-05-17 2021-08-31 세다르스-신나이 메디칼 센터 크론병과 연관된 tnfsf15와 dcr3의 변이체
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
EP3337509A4 (en) 2015-08-21 2019-01-02 The Children's Hospital of Philadelphia Methods of treating autoimmune conditions in patients with genetic variations in dcr3 or in a dcr3 network gene
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
JP7082945B2 (ja) 2016-03-17 2022-06-09 シーダーズ―シナイ メディカル センター Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法
KR102481305B1 (ko) * 2016-05-20 2022-12-26 세다르스-신나이 메디칼 센터 유전자에 기반한 염증성 장 질환의 진단
CA3111819A1 (en) * 2018-09-07 2020-03-12 The Children's Hospital Of Philadelphia Compositions and methods for the diagnosis and treatment of lymphatic system disorders
WO2020232125A1 (en) 2019-05-14 2020-11-19 Prometheus Biosciences, Inc. Tl1a patient selection methods, systems, and devices
AU2020346580A1 (en) * 2019-09-13 2022-03-31 Kyowa Kirin Co., Ltd. DcR3 variant
WO2022103961A1 (en) * 2020-11-13 2022-05-19 Prometheus Biosciences, Inc. Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
WO2025038473A1 (en) 2023-08-11 2025-02-20 Paragon Therapeutics, Inc. Tl1a binding antibodies and methods of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20090186034A1 (en) * 2006-12-19 2009-07-23 Genetech, Inc. Gene expression markers for inflammatory bowel disease
WO2008106451A2 (en) * 2007-02-26 2008-09-04 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2009052512A2 (en) 2007-10-19 2009-04-23 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose and predict inflammatory bowel disease
AU2009215441B2 (en) * 2008-02-19 2015-07-02 The Children's Hospital Of Philadelphia Identification of pediatric onset inflammatory bowel disease loci and methods of use thereof for the diagnosis and treatment of the same
WO2010118210A1 (en) * 2009-04-08 2010-10-14 Cedars-Sinai Medical Center Methods of predicting complication and surgery in crohn's disease
CA2758531C (en) * 2009-04-14 2018-11-13 Derren Barken Inflammatory bowel disease prognostics
AU2011317149B2 (en) 2010-10-18 2015-05-07 Société des Produits Nestlé S.A. Methods for determining anti-drug antibody isotypes
ES2530175T3 (es) 2011-02-17 2015-02-26 Nestec S.A. Ensayos para la detección de autoanticuerpos contra fármacos anti-TNF
WO2012161856A1 (en) 2011-05-20 2012-11-29 Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
US20140170157A1 (en) 2011-06-15 2014-06-19 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications
EP2565277A1 (en) 2011-09-05 2013-03-06 Progenika Biopharma, S.A. Method for predicting radiographic severity in ankylosing spondylitis
SG11201401536QA (en) 2011-10-21 2014-05-29 Nestec Sa Methods for improving inflammatory bowel disease diagnosis
KR102295125B1 (ko) 2013-05-17 2021-08-31 세다르스-신나이 메디칼 센터 크론병과 연관된 tnfsf15와 dcr3의 변이체
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
JP7082945B2 (ja) 2016-03-17 2022-06-09 シーダーズ―シナイ メディカル センター Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法

Similar Documents

Publication Publication Date Title
JP2020127437A5 (enExample)
JP2018148931A5 (enExample)
Li et al. Seroprevalence of hepatitis E virus infection, rural southern People’s Republic of China
JP2016526875A5 (enExample)
Wang et al. Prevalence of noroviruses and sapoviruses in swine of various ages determined by reverse transcription-PCR and microwell hybridization assays
Shukla et al. Hepatitis E virus infection among animals in northern India: an unlikely source of human disease
Rodríguez-Díaz et al. Detection and characterization of waterborne gastroenteritis viruses in urban sewage and sewage-polluted river waters in Caracas, Venezuela
Stang et al. Characterization of virus isolates by particle-associated nucleic acid PCR
McInnes et al. The emergence of squirrelpox in I reland
Bui et al. Median infectious dose of human norovirus GII. 4 in gnotobiotic pigs is decreased by simvastatin treatment and increased by age
Bialasiewicz et al. Association of micropapillary urothelial carcinoma of the bladder and BK viruria in kidney transplant recipients
Bergin et al. Novel calicivirus identified in rabbits, Michigan, USA
Caine et al. A single mutation in the VP1 of enterovirus 71 is responsible for increased virulence and neurotropism in adult interferon-deficient mice
JP2008508859A5 (enExample)
Kong et al. Detection methods of cyprinid herpesvirus 2 infection in silver crucian carp (Carassius auratus gibelio) via a pORF 72 monoclonal antibody
Kim et al. Molecular epidemiology of human norovirus in Korea in 2013
CN114787193A (zh) 抗聚合酶的单克隆抗体及其应用
Diep et al. Appearance of US‐like porcine epidemic diarrhoea virus (PEDV) strains before US outbreaks and genetic heterogeneity of PEDV s collected in Northern Vietnam during 2012–2015
Mohamed et al. Comparative susceptibility of eastern cottontails and New Zealand white rabbits to classical rabbit haemorrhagic disease virus (RHDV) and RHDV2
Hara et al. Long‐term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos (t) ide‐naïve chronic hepatitis B patients
Gurgel et al. Prevalence of human papillomavirus variants and genetic diversity in the L1 gene and long control region of HPV16, HPV31, and HPV58 found in North‐East Brazil
WO2014165240A1 (en) Synbodies for detection of human norovirus
Shen et al. Genetic characterization of porcine sapoviruses identified from pigs during a diarrhoea outbreak in Iowa, 2019
SG144692A1 (en) Antigenic proteins of shrimp white spot syndrome virus and uses thereof
Grom et al. Bovine viral diarrhoea (BVD) infections–control and eradication programme in breeding herds in Slovenia